Nash Pharmaceuticals Announces Positive Pre-Clinical Results From a Second Study for Chronic Kidney Disease

Nash Pharmaceuticals Inc., a wholly owned subsidiary of UF startup Breathtec Biomedical Inc., is pleased to announce that in a new recent in vivo animal study for Chronic Kidney Disease (CKD), the activity of NP-135 was confirmed, and two additional compounds, NP-160 and NP-251 were identified as new lead compounds in a unilateral ureteral obstruction (UUO) mouse model of kidney fibrosis.

Data from this study demonstrated that clinically relevant doses resulted in statistically significant improvements in the reduction in fibrosis in the UUO model as measured by Sirius Red staining over untreated controls.

Learn more about Nash Pharmaceuticals Announces Positive Pre-Clinical Results From a Second Study for Chronic Kidney Disease as well as 2 Additional Lead Targets.